Pharmacyclics, Inc.

Axys Pharmaceuticals, Inc.

Merck Sharp + Dohme Corp.

Merck Frosst Canada, Inc.

Merck Canada Inc.

Chitra Baskaran

Joseph J Buggy

Martin Sendzik

James Robinson

Erik J Verner

Michael J Green

Cheuk K Lau

Michel Therien

Jacques Yves Gauthier

Serge Leger

Cameron Black

Chun Sing Li

Bernard Hirschbein

James T Palmer

Christophe Mellon

Dan McKay

Vouy-Linh Truong

James William Janc

Christopher I Bayly

Eric J Verner

Vouy Linh Truong

Dan Mckay

James W Janc

The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.

Hydroxamates as therapeutic agents

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

Cathepsin cysteine protease inhibitors

Growing community of inventors

Foster City, CA, United States of America

Chitra Baskaran